Kocoglu, H. Et Al. 2016. Erlotinib as first line treatment in a NSCLC patient with choroidal metastasis and with EGFR exon 19 deletion. Journal of B.U.ON. , vol.21, no.3 , 754-755.

Kocoglu, H., Karaca, M., Turkay, R., & Tural, D., (2016). Erlotinib as first line treatment in a NSCLC patient with choroidal metastasis and with EGFR exon 19 deletion. Journal of B.U.ON. , vol.21, no.3, 754-755.

Kocoglu, Hakan Et Al. "Erlotinib as first line treatment in a NSCLC patient with choroidal metastasis and with EGFR exon 19 deletion," Journal of B.U.ON. , vol.21, no.3, 754-755, 2016

Kocoglu, Hakan Et Al. "Erlotinib as first line treatment in a NSCLC patient with choroidal metastasis and with EGFR exon 19 deletion." Journal of B.U.ON. , vol.21, no.3, pp.754-755, 2016

Kocoglu, H. Et Al. (2016) . "Erlotinib as first line treatment in a NSCLC patient with choroidal metastasis and with EGFR exon 19 deletion." Journal of B.U.ON. , vol.21, no.3, pp.754-755.

@article{article, author={Hakan Kocoglu Et Al. }, title={Erlotinib as first line treatment in a NSCLC patient with choroidal metastasis and with EGFR exon 19 deletion}, journal={Journal of B.U.ON.}, year=2016, pages={754-755} }